No Detail Found!

Drug-drug interactions with azithromycin during COVID-19: An evidence of contribution towards patient mortality

Author(s)
Sidra Tanwir Department of Pharmacy Practice, Faculty of Pharmacy and Pharmaceutical Sciences, Ziauddin University,Karachi,Pakistan
Arif Sabah Department of Pharmacy Practice, Faculty of Pharmacy and Pharmaceutical Sciences, Ziauddin University,Karachi,Pakistan
Ambrina Khatoon Department of Molecular Medicine, Ziauddin University,Karachi,Pakistan
Aysha Malik Department of Pharmacy Practice, Baqai Institute of Pharmaceutical Sciences, Baqai Medical University,Karachi,Pakistan
Abstract
The study was conducted to evaluate the prevalence of Drug-Drug Interactions (DDIs) of Azithromycin and its impact on patient mortality and microbial resistance during the first wave of COVID-19. The study was performed in tertiary care hospitals located in various areas of Karachi, Pakistan. A cross sectional retrospective study on a sample size of 300 patients was conducted (Jan - Dec 2020) on in-patients receiving Azithromycin as part of their therapeutic regimen. Data was collected using a structured and validated tool. The Medscape Drug Reference database was applied to assess the DDIs. The presence of DDIs was observed in 224 patients (75 %) involving 28 drugs with a total of 346 interactions. Among them, majority (60 %) were severe followed by moderate (33 %) and mild interactions (7 %). Among 300 patients, a total of 41 mortalities was observed with highest percentage (90%) in patients with drugs causing severe interactions i.e. enoxaparin and hydroxychloroquine. The moderate interaction group exhibited 10% mortality involving piperacillin. Additionally, out of 346 interactions, only one due to calcium carbonate was found to affect the bioavailability of azithromycin. Our data reveals the high prevalence of DDIs with Azithromycin during the first wave of COVID-19, which has most likely contributed towards the mortality.
Publication Details
Page(s) 983-988
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 38, Issue: 3, Year: 2025

Request the full text from PASTIC

Keywords
COVID-19, Mortality, Azithromycin, drug-drug interactions, Covid-19
References
Adamiszak .2022 .Drug interactions in COVID-19 treatment. Systematic review. J Farm Pol, 78(7) : 390-402.
Al-Azzam ,Barbara R Conway and Mamoon A Aldeyab .2021 .An assessment of the impact of coronavirus disease (COVID-19) pandemic on national antimicrobial consumption in Jordan. Antibiot, 10(6) : 690.
Ayerbe ,Salma Ayis .2022 .Azithromycin in patients with COVID-19: a systematic review and metaanalysis. J. Antimicrob. Chemother, 77(2) : 303-309.
Barnes ,Geoffrey D,Allison Burnett,Stacy Ellsworth Burnett,David Garcia Burnett .2020 .Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: Interim clinical guidance from the anticoagulation forum. J. Thromb. Thrombolysis, 50 : 72-81.
Cantudo-Cuenca MD,Ramon MorilloVerdugo MD .2021 .Drug-drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain. Sci. Rep, 11(1) : 1241-4.
Chen ,Yang Qiu,Jingli Wang,Wei Wang .2020 .Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet, 395(10223) : 507-513.
Conti ,Raschi .2022 .Identification of drug interaction adverse events in patients with COVID-19: A systematic review. JAMA, 5(4) : e227970-e227970.
Doan Ramatou,Maliki Ramatou,Lebas Ramatou .2020 ."Macrolide and nonmacrolide resistance with mass azithromycin distribution. NEJM, 383(20) : 1941-1950.
Dorgalaleh ,Akbar .2020 .Bleeding and bleeding risk in COVID-19. , 46(7) : 815-818.
Gautret ,Jean-Christophe Lagier,Piseth Seng Lagier .2020 .Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis, 34 : 101663.
Hodge Saye,Khoo Saye,Antimicrob Saye .2020 .Drug interactions: A review of the unseen danger of experimental COVID-19 therapies. , 75(12) : 3417-3424.
Iloanusi Ekere J Essien. .2021 .Polypharmacy among COVID-19 patients: A systematic review. JAPhA., 61(5) : e14-e25.
Kim ,Tae-Ho Hwang .2020 .Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network metaanalysis. PLoS Med, 17(12) : e1003501.
Kournoutou Georgia G,George Dinos Georgia G .2022 .Azithromycin through the Lens of the COVID-19 Treatment. , 11(8) : 1063.
Li T,Higgins JPT,Deeks JJ,J Higgins JPT,Chandler J,Cumpston M,Li T,Page MJ,Welch VA .2021 .Collecting data. In Cochrane Handbook for Systematic Reviews of Interventions, 23 : 109-141.
Manjhi .2021 .Drug-drug interactions in patients with COVID-19: A retrospective study at a tertiary care Hospital in Eastern India. Maedica, 16(2) : 163.
Medscape .2023 .. , : .
Pourhoseingholi ,Rahimzadeh .2013 .Sample size calculation in medical studies. GHFBB, 6(1) : 14.
Rosenberg ,Eli S,Elizabeth M Dufort,Udo Tomoko,Jack DeHovitz Tomoko .2020 .Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-. , 323(24) : 2493-2502.
Soherwardi Bharti,Chogtu P,Faizal P .2012 .Surveillance of the potential drug-drug interactions in the medicine department of a tertiary care Hospital. JCDR., 6(7) : 1258-61.
Epidemiology Team .2020 .The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-. , 2(8) : 113-122.
Thomas ,Mari R,Marie Scully R,Hematol Am. J. .2022 .Clinical features of thrombosis and bleeding in COVID-19.. , 140(3) : 184-195.
Mustafa Ul .2021 .Antimicrobial consumption among hospitalized patients with COVID-19 in Pakistan. Chia Siang Kow and Syed Shahzad Hasan, 3(8) : 1691-1695.
Zequn ,Jiangfang .2021 .Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel. Eur. J., : .
. .. , 893 : 173813.
0

Citations

0

Downloads

93

Views